Novartis acquisition

Quote

anonymous

Guest
I saw the news about the Novartis acquisition. Will MorphoSys sales representatives still have positions? Will you transition to Novartis? Incyte? What is the latest?
 












anonymous said:
We have no answers yet. Incyte deal did not include sales reps. We are in limbo.
Click to expand...
When Novartis is laying off 8,000 people between 2022 to 2024. I highly doubt it. In Germany everyone is canned. Novartis didnt buy Morphosys for pela (a ok MF medication) but with less than 20,000 people in the United States with about 10 new medications being FDA approved last year and this year. Novartis bought Morphosys for their development program. Pela are you kidding me? The only monotherapy MF study with pela is if they are JAK2 resistant. Combination therapy in MF is a joke.
 












Do you really believe that Novartis will keep people when they are into a 2 year plan to reduce their headcount by 10,000 employees between 2022 and 2024. Plus they canned a couple hundred people since 2024 began. MONJUVI is not yours anymore. All you have is a medication for MF. You dont have to think much that Morphosys had this planned over the past 2 years we they started buying the R&D platform .
 
























Top Bottom
Back
Quote